A detailed history of State Street Corp transactions in Nuvalent, Inc. stock. As of the latest transaction made, State Street Corp holds 1,243,099 shares of NUVL stock, worth $113 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,243,099
Previous 1,326,040 6.25%
Holding current value
$113 Million
Previous $101 Million 26.42%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $5.59 Million - $9.3 Million
-82,941 Reduced 6.25%
1,243,099 $127 Million
Q2 2024

Aug 14, 2024

SELL
$62.76 - $81.61 $11.8 Million - $15.3 Million
-188,066 Reduced 12.42%
1,326,040 $101 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $13.5 Million - $16.7 Million
-187,128 Reduced 11.0%
1,514,106 $114 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $18.7 Million - $35.4 Million
440,768 Added 34.97%
1,701,234 $125 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $3.62 Million - $4.61 Million
92,477 Added 7.92%
1,260,466 $57.9 Million
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $2.94 Million - $5.58 Million
124,786 Added 11.96%
1,167,989 $49.3 Million
Q1 2023

May 15, 2023

BUY
$25.42 - $33.52 $5.34 Million - $7.04 Million
210,155 Added 25.23%
1,043,203 $27.2 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $9.94 Million - $19.6 Million
538,416 Added 182.74%
833,048 $24.8 Million
Q3 2022

Nov 15, 2022

BUY
$13.55 - $19.92 $139,199 - $204,638
10,273 Added 3.61%
294,632 $5.73 Million
Q2 2022

Aug 15, 2022

BUY
$7.4 - $15.07 $428,608 - $872,854
57,920 Added 25.58%
284,359 $3.86 Million
Q1 2022

May 16, 2022

BUY
$11.65 - $19.57 $675,536 - $1.13 Million
57,986 Added 34.42%
226,439 $3.15 Million
Q4 2021

Feb 14, 2022

BUY
$18.01 - $30.1 $532,051 - $889,214
29,542 Added 21.27%
168,453 $3.21 Million
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $2.54 Million - $5.33 Million
138,911 New
138,911 $3.13 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.